SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin receives EIR from USFDA for Nagpur Unit-1 manufacturing facility

29 Sep 2023 Evaluate

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Nagpur Unit-1 manufacturing facility that manufactures oral solid dosage forms. The EIR was issued post the last inspection of the facility conducted in July 2023. The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2476.10 77.40 (3.23%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: